DUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), formerly SuperGen, Inc., today reported financial results for the third quarter ended September 30, 2011. The Company reported a net loss for the 2011 third quarter of $1.1 million, or $0.01 per basic and diluted share, compared with net income of $3.9 million, or $0.06 per basic and diluted share, for the same prior year period. The Company reported net income for the nine months ended September 30, 2011 of $5.3 million, or $0.08 per basic share and $0.07 per diluted share, compared with a net income of $9.5 million, or $0.16 per basic and diluted share, for the same prior year period.
